A Phase 2/3 interventional study of tividenofusp alfa and idursulfase in Mucopolysaccharidosis II, sponsored by Denali Therapeutics Inc.. Active, not recruiting at 30 sites in 14 countries. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Denali Therapeutics Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing idursulfase in Mucopolysaccharidosis II — none open to participants now, 2 under way, 2 of them phase 3. idursulfase · Mucopolysaccharidosis II.
Among the 12 studies testing idursulfase in Mucopolysaccharidosis II, this one is the 3rd largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 2/3, and was the 10th registered.
77 studies on the registry are indexed under Mucopolysaccharidosis II; 8 are open to participants now.
Browse Mucopolysaccharidosis II studies →None of the 12 studies testing idursulfase in Mucopolysaccharidosis II is open now. The open studies under Mucopolysaccharidosis II, anywhere →
idursulfase: first FDA approval 2006 (ELAPRASE), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 4 Mucopolysaccharidosis II studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 2 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 7 · Phase 4 4
First in 2003; this study’s year is marked. 2 started in 2022.
This study's enrollment of 65 is above the median of 22 across 48 interventional studies indexed under Mucopolysaccharidosis II.
Median enrollment 30 across the 12 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 4 most frequent:
Denali Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Denali Therapeutics Inc. has 4 studies filed under Mucopolysaccharidosis II — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing idursulfase in Mucopolysaccharidosis II, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II).
Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tividenofusp alfa · Drug: idursulfase
Drug: tividenofusp alfa · Drug: idursulfase
Participants who meet pre-specified criteria may receive DNL310 or idursulfase
Drug: tividenofusp alfa · Drug: idursulfase
Intravenous repeating dose
Intravenous repeating dose
Ratio to baseline in cerebrospinal fluid (CSF) heparan sulfate (HS) concentration (Cohort A)
Time frame: 24 weeks
Change from baseline in the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3)(Cohort A)
Time frame: 96 weeks
Change from baseline in the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III)(Cohort A only)
Time frame: 96 weeks
Change from baseline in the Vineland-3 Adaptive Behavior Composite (ABC) score (Cohort A only)
Time frame: 96 weeks
Ratio to baseline in serum neurofilament light chain (NfL) (Cohort A only)
Time frame: 96 weeks
Change from baseline in distance walked in the Six-Minute Walk Test (6MWT; Cohort B only)
Time frame: 48 weeks
Ratio to baseline in the sum of urine HS and dermatan sulfate (DS) concentrations (normalized to creatinine) (Cohorts A and B)
Time frame: up to 48 weeks
Liver volume within the normal range (normal vs abnormal) as measured by magnetic resonance imaging (MRI) (Cohorts A and B)
Time frame: 48 weeks
Spleen volume within the normal range (normal vs abnormal) as measured by MRI (Cohorts A and B)
Time frame: 48 weeks
Improvement in Parent/Caregiver Global Impression of Change (CaGI-C) Overall MPS II (Cohorts A and B)
Time frame: 48 weeks
Plan to share: No
Started Jul 2022 (actual). Primary completion is estimated for Dec 2027, 65 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tividenofusp alfa · Idursulfase
Denali Therapeutics Inc.